JP2022529703A - 腫瘍治療薬及びその応用 - Google Patents

腫瘍治療薬及びその応用 Download PDF

Info

Publication number
JP2022529703A
JP2022529703A JP2021562118A JP2021562118A JP2022529703A JP 2022529703 A JP2022529703 A JP 2022529703A JP 2021562118 A JP2021562118 A JP 2021562118A JP 2021562118 A JP2021562118 A JP 2021562118A JP 2022529703 A JP2022529703 A JP 2022529703A
Authority
JP
Japan
Prior art keywords
cdr2
chain cdr1
seq
cdr3 sequences
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021562118A
Other languages
English (en)
Japanese (ja)
Inventor
▲剛▼ 徐
博 ▲陳▼
▲瑩▼ 王
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keymed Biosciences Co Ltd
Original Assignee
Keymed Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keymed Biosciences Co Ltd filed Critical Keymed Biosciences Co Ltd
Publication of JP2022529703A publication Critical patent/JP2022529703A/ja
Priority to JP2023129054A priority Critical patent/JP7547581B2/ja
Priority to JP2024146208A priority patent/JP2024167313A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021562118A 2019-04-19 2020-04-15 腫瘍治療薬及びその応用 Pending JP2022529703A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023129054A JP7547581B2 (ja) 2019-04-19 2023-08-08 腫瘍治療薬及びその応用
JP2024146208A JP2024167313A (ja) 2019-04-19 2024-08-28 腫瘍治療薬及びその応用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910315634 2019-04-19
CN201910315634.9 2019-04-19
PCT/CN2020/084991 WO2020211792A1 (zh) 2019-04-19 2020-04-15 肿瘤治疗剂及其应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023129054A Division JP7547581B2 (ja) 2019-04-19 2023-08-08 腫瘍治療薬及びその応用

Publications (1)

Publication Number Publication Date
JP2022529703A true JP2022529703A (ja) 2022-06-23

Family

ID=72837018

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021562118A Pending JP2022529703A (ja) 2019-04-19 2020-04-15 腫瘍治療薬及びその応用
JP2023129054A Active JP7547581B2 (ja) 2019-04-19 2023-08-08 腫瘍治療薬及びその応用
JP2024146208A Pending JP2024167313A (ja) 2019-04-19 2024-08-28 腫瘍治療薬及びその応用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023129054A Active JP7547581B2 (ja) 2019-04-19 2023-08-08 腫瘍治療薬及びその応用
JP2024146208A Pending JP2024167313A (ja) 2019-04-19 2024-08-28 腫瘍治療薬及びその応用

Country Status (5)

Country Link
US (1) US20220372112A1 (enExample)
EP (1) EP3960766A4 (enExample)
JP (3) JP2022529703A (enExample)
CN (2) CN119613553A (enExample)
WO (1) WO2020211792A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11407828B2 (en) 2019-02-01 2022-08-09 Novarock Biotherapeutics, Ltd. Anti-CLauDiN 18 antibodies and methods of use thereof
CN114366818B (zh) * 2020-10-15 2025-02-25 上海美雅珂生物技术有限责任公司 抗体药物偶联物及其应用
EP4299593A4 (en) * 2021-04-02 2025-12-10 Oricell Therapeutics Co Ltd CLDN18.2 ANTIGEN-BINDING PROTEIN AND ITS USE
JP2024540062A (ja) 2021-11-05 2024-10-31 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド 抗ｃｌｄｎ１８．２抗体及びその用途
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025088105A1 (en) 2023-10-27 2025-05-01 Keymed Biosciences (Chengdu) Co., Ltd Cancer treatment with anti-claudin 18.2 adc
WO2025086270A1 (en) 2023-10-27 2025-05-01 Keymed Biosciences (Chengdu) Co., Ltd. Cancer treatment with anti-claudin 18.2 adc
WO2025086268A1 (en) 2023-10-27 2025-05-01 Keymed Biosciences (Chengdu) Co., Ltd. Cancer treatment with anti-claudin 18.2 adc
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015517476A (ja) * 2012-05-09 2015-06-22 ガニメド ファーマシューティカルズ アーゲー 癌診断に有用なクローディン１８．２に対する抗体
JP2016500059A (ja) * 2012-11-13 2016-01-07 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ クローディンを発現するガン疾患を処置するための剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
WO2014127785A1 (en) * 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
JP7587921B2 (ja) * 2016-07-08 2024-11-21 クレージュ メディカル カンパニー，リミテッド 抗クローディンタンパク質１８ａ２の抗体及びその応用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015517476A (ja) * 2012-05-09 2015-06-22 ガニメド ファーマシューティカルズ アーゲー 癌診断に有用なクローディン１８．２に対する抗体
JP2016500059A (ja) * 2012-11-13 2016-01-07 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ クローディンを発現するガン疾患を処置するための剤

Also Published As

Publication number Publication date
CN113748133A (zh) 2021-12-03
EP3960766A4 (en) 2022-12-07
JP7547581B2 (ja) 2024-09-09
JP2024167313A (ja) 2024-12-03
JP2023153984A (ja) 2023-10-18
WO2020211792A1 (zh) 2020-10-22
US20220372112A1 (en) 2022-11-24
CN113748133B (zh) 2024-07-02
EP3960766A1 (en) 2022-03-02
CN119613553A (zh) 2025-03-14

Similar Documents

Publication Publication Date Title
JP7547581B2 (ja) 腫瘍治療薬及びその応用
JP7143452B2 (ja) ＣＤ４７とＳＩＲＰａの相互作用を遮断できる抗体及びその応用
US11161904B2 (en) Anti-PD-1 antibody and use thereof
CN111454357B (zh) 一种含有抗体的肿瘤治疗剂的开发和应用
CA3110749A1 (en) Anti-pd-1/vegfa bifunctional antibody, pharmaceutical composition thereof and use thereof
WO2020168555A1 (zh) Cd3抗原结合片段及其应用
CN111808194A (zh) 一种结合密蛋白的用于治疗癌症的人源化抗体
JP7734386B2 (ja) 医薬組成物、その製造方法及び用途
KR20230117183A (ko) 새로운 종양 인게이저 치료 약물의 개발 및 이의 용도
RU2831838C2 (ru) Биспецифическое антитело анти-HER2/анти-4-1BB и его применение
WO2024002308A1 (zh) 一种新型多特异肿瘤抑制剂的开发和应用
EA049135B1 (ru) Бифункциональное антитело против pd-1 и против vegfa, его фармацевтическая композиция и его применение

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230509

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231128